Portada Simposios - Supplements - Haematologica

284 Haematologica (ed. esp.), volumen 85, supl. 2, octubre 2000
24. Fong Y, Tracey KJ, Moldawer LL et al. Antibodies to cachectin/tumor
necrosis factor reduce interleukin 1 beta and interleukin 6 appearance
during lethal bacteremia. J Exp Med 1989; 170: 1627-1633.
25. Endo S, Inada K, Inoue Y et al. Two types of septic shock classified by the
plasma levels of cytokines and endotoxin. Circ Shock 1992; 38: 264-274.
26. ten Cate JW, van der Poll T, Levi M, ten Cate H, van Deventer SJ. Cytokines:
triggers of clinical thrombotic disease. Thromb Haemost 1997;
78: 415-419.
27. Boermeester MA, van Leeuwen PA, Coyle SM, Wolbink GJ, Hack CE,
Lowry SF. Interleukin-1 blockade attenuates mediator release and dysregulation
of the hemostatic mechanism during human sepsis. Arch
Surg 1995; 130: 739-748.
28. Fischer E, Marano MA, Van Zee KJ et al. Interleukin-1 receptor blockade
improves survival and hemodynamic performance in Escherichia coli
septic shock, but fails to alter host responses to sublethal endotoxemia.
J Clin Invest 1992; 89: 1551-1557.
29. Jansen PM, Boermeester MA, Fischer E et al. Contribution of interleukin-1
to activation of coagulation and fibrinolysis, neutrophil degranulation,
and the release of secretory-type phospholipase A2 in sepsis:
studies in nonhuman primates after interleukin-1 alpha administration
and during lethal bacteremia. Blood 1995; 86: 1027-1034.
30. Shalaby MR, Waage A, Aarden L, Espevik T. Endotoxin, tumor necrosis
factor-alpha and interleukin 1 induce interleukin 6 production in
vivo. Clin Immunol Immunopathol 1989; 53: 488-498.
31. Van der Poll T, Levi M, Hack CE et al. Elimination of interleukin 6 attenuates
coagulation activation in experimental endotoxemia in chimpanzees.
J Exp Med 1994; 179: 1253-1259.
32. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB.
Tissue factor pathway inhibitor reduces mortality from Escherichia coli
septic shock. J Clin Invest 1993; 91: 2850-2856.
33. Hack CE, De Groot ER, Felt-Bersma RJ et al. Increased plasma levels of
interleukin-6 in sepsis. Blood 1989; 74: 1704-1710.
34. Taylor FB Jr, Chang AC, Peer GT et al. DEGR-factor Xa blocks disseminated
intravascular coagulation initiated by Escherichia coli without
preventing shock or organ damage. Blood 1991; 78: 364-368.
35. Muñoz MC, Montes R, Hermida J, Orbe J, Páramo JA, Rocha E. Effect
of the administration of recombinant hirudin and/or tissue-plasminogen
activator (t-PA) on endotoxin-induced disseminated intravascular
coagulation model in rabbits. Br J Haematol 1999; 105: 117-121.
36. Taylor FB Jr, Chang A, Ruf W et al. Lethal E. coli septic shock is prevented
by blocking tissue factor with monoclonal antibody. Circ Shock
1991; 33: 127-134.
37. Lauw FN, Dekkers PE, te Velde AA et al. Interleukin-12 induces sustained
activation of multiple host inflammatory mediator systems in chimpanzees.
J Infect Dis 1999; 179: 646-652.
38. Kuipers B, van der Poll T, Levi M et al. Platelet-activating factor antagonist
TCV-309 attenuates the induction of the cytokine network in experimental
endotoxemia in chimpanzees. J Immunol 1994; 152: 2438-2446.
39. Held TK, Weihua X, Yuan L, Kalvakolanu DV, Cross AS. Gamma interferon
augments macrophage activation by lipopolysaccharide by two
distinct mechanisms, at the signal transduction level and via an autocrine
mechanism involving tumor necrosis factor alpha and interleukin-1.
Infect Immun 1999; 67: 206-212.
40. Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10.
Annu Rev Immunol 1993; 11: 165-190.
41. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects
mice from lethal endotoxemia. J Exp Med 1993; 177: 1205-1208.
42. Marchant A, Bruyns C, Vandenabeele P et al. Interleukin-10 controls interferon-gamma
and tumor necrosis factor production during experimental
endotoxemia. Eur J Immunol 1994; 24: 1167-1171.
43. Pradier O, Gerard C, Delvaux A et al. Interleukin-10 inhibits the induction
of monocyte procoagulant activity by bacterial lipopolysaccharide.
Eur J Immunol 1993; 23: 2700-2703.
44. Van der Poll T, Jansen PM, Montegut WJ et al. Effects of IL-10 on systemic
inflammatory responses during sublethal primate endotoxemia.
J Immunol 1997; 158: 1971-1975.
45. Pajkrt D, van der Poll T, Levi M et al. Interleukin-10 inhibits activation of
coagulation and fibrinolysis during human endotoxemia. Blood 1997;
89: 2701-2705.
46. Kremer JP, Jarrar D, Steckholzer U, Ertel W. Interleukin-1, -6 and tumor
necrosis factor-alpha release is down-regulated in whole blood from
septic patients. Acta Haematol 1996; 95: 268-273.
47. Collen D, Lijnen HR. Molecular basis of fibrinolysis, as relevant for thrombolytic
therapy. Thromb Haemost 1995; 74: 167-171.
48. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B,
couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin
complex. J Biol Chem 1996; 271: 16603-16608.
49. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated
protein C in clots formed from plasma is TAFI-dependent. Blood 1996;
88: 2093-2100.
50. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis.
Blood 1999; 94: 2735-2743.
51. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis
inhibitor and the risk for deep vein thrombosis. Blood 2000;
95: 2855-2859.
52. Colucci M, Páramo JA, Collen D. Generation in plasma of a fast-acting
inhibitor of plasminogen activator in response to endotoxin stimulation.
J Clin Invest 1985; 75: 818-824.
53. Páramo JA, Pérez JL, Serrano M, Rocha E. Types 1 and 2 plasminogen
activator inhibitor and tumor necrosis factor alpha in patients with sepsis.
Thromb Haemost 1990; 64: 3-6.
54. Gómez C, Páramo JA, Colucci M, Rocha E. Effect of heparin and/or antithrombin
III on the generation of endotoxin-induced plasminogen
activator inhibitor. Thromb Haemost 1989; 62: 694-698.
55. Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated
mice correlates with decreases in the expression of urokinase-type
but not tissue-type plasminogen activator. J Clin Invest 1996;
97: 2440-2451.
56. Hermida J, Montes R, Muñoz MC, Orbe J, Páramo JA, Rocha E. Effects
of low molecular weight heparin, alone or combined with antithrombin
III, on mortality, fibrin deposits and hemostatic parameters in
endotoxin-induced disseminated intravascular coagulation in rabbits.
Am J Hematol 1999; 60: 6-11.
57. Van Hinsberg VW, Sprengers ED, Kooistra T. Effect of thrombin on the
production of plasminogen activators and PA inhibitor-1 by human
foreskin microvascular endothelial cells. Thromb Haemost 1987; 57:
148-153.
58. Chordá C, Páramo JA, Rocha E. Comparison of the effects of unfractionated
heparin, low molecular weight heparin and hirudin (Revasc TM )
on the fibrinolytic potential of cultured human umbilical vein endothelial
cells. Fibrinolysis 1996; 10: 43-48.
59. Paloma MJ, Páramo JA, Rocha E. Effect of DDAVP on endotoxin-induced
intravascular coagulation in rabbits. Thromb Haemost 1992; 68:
306-309.
60. Paloma MJ, Páramo JA, Rocha E. Endotoxin-induced intravascular coagulation
in rabbits: effect of tissue plasminogen activator vs urokinase
of PAI generation, fibrin deposits and mortality. Thromb Haemost
1995; 74: 1578-1582.
61. Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective
and fibrin-specific clot lysis by a zymogen precursor form of urokinase
(pro-urokinase). A study in vitro and in two animal species. J Clin
Invest 1984; 73: 1731-1739.
62. Esmon CT. Introduction: are natural anticoagulants candidates for modulating
the inflammatory response to endotoxin Blood 2000; 95:
1113-1116.
63. Montes R, Declerck PJ, Calvo A et al. Prevention of renal fibrin deposition
in endotoxin-induced DIC through inhibition of PAI-1. Thromb
Haemost 2000 (en prensa).
64. Abrahamsson T, Nerme V, Stromqvist M et al. Anti-thrombotic effect of
a PAI-1 inhibitor in rats given endotoxin. Thromb Haemost 1996; 75:
118-126.
65. Suffredini AF. Current prospects for the treatment of clinical sepsis. Crit
Care Med 1994; 22: S12-18.
66. Cohen J, Heumann D, Glauser MP. Do monoclonal antibodies and anticytokines
still have a future in infectious diseases Am J Med 1995; 99:
45S-52S; discussion 52S-53S.
67. Sasayama S, Matsumori A. Vesnarinone: a potential cytokine inhibitor.
J Card Fail 1996; 2: 251-258.
68. Gullo A, Berlot G. Ingredients of organ dysfunction or failure. World J
Surg 1996; 20: 430-436.
69. Baue AE, Durham R, Faist E. Systemic inflammatory response syndrome
(SIRS), multiple organ dysfunction syndrome (MODS), multiple organ
failure (MOF): are we winning the battle Shock 1998; 10: 79-89.
70. Cross A. Novel approaches to the treatment of sepsis: lessons learned
and future directions. Shock 1996; 6: S71-74.
71. Abraham E. Why immunomodulatory therapies have not worked in
sepsis. Intensive Care Med 1999; 25: 556-566.
72. Pittet D, Harbarth S, Suter PM et al. Impact of immunomodulating therapy
on morbidity in patients with severe sepsis. Am J Respir Crit Care
Med 1999; 160: 852-857.
73. Abraham E. Cytokine modifiers: pipe dream or reality Chest 1998;
113: 224S-227S.
74. Bozza M, Satoskar AR, Lin G et al. Targeted disruption of migration inhibitory
factor gene reveals its critical role in sepsis. J Exp Med 1999;
189: 341-346.
75. Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin
lethality in mice. Science 1999; 285: 248-251.
76. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B:
a pivotal role in the systemic inflammatory response syndrome and new
target for therapy. Intensive Care Med 1998; 24: 1131-1138.